Hs 445 (ATCC® HTB-146)

Organism: Homo sapiens, human  /  Disease: Hodgkin's disease; Hodgkin's lymphoma

Permits and Restrictions

View Permits

Organism Homo sapiens, human
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 2 Cells Contain HERPESVIRUS
Disease Hodgkin's disease; Hodgkin's lymphoma
Age 56 years
Gender female
Ethnicity Caucasian
Applications
Hs 445 was derived in 1970 from an intra-abdominal lymph node of a patient with stage 1 Hodgkin's disease.
0.3% to 0.5% of the cells are positive for EBV early antigen and virion antigen by immunofluorescence.
Derivation
Hs 445 was derived in 1970 from an intra-abdominal lymph node of a patient with stage 1 Hodgkin's disease.
Clinical Data
Hs 445 was derived in 1970 from an intra-abdominal lymph node of a patient with stage 1 Hodgkin's disease.
female
Caucasian
56 years
Tumorigenic Yes
Effects
Yes, in X-irradiated or anti lymphocyte serum treated nude mice
No, in anti thymocyte serum treated Swiss mice
Comments
Hs 445 was derived in 1970 from an intra-abdominal lymph node of a patient with stage 1 Hodgkin's disease.
By electron microscopy, herpesvirus-like particles have been seen.
0.3% to 0.5% of the cells are positive for EBV early antigen and virion antigen by immunofluorescence.
Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing
Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Establish new cultures at 4 X 10 exp5 cells/ml and maintain at between 4 X 10 exp5 and 1 X 10 exp6 cells/ml.
Cryopreservation
Culture medium, 95%; DMSO, 5%
STR Profile
Amelogenin: X
CSF1PO: 11,10.3
D13S317: 11,13
D16S539: 9,11
D5S818: 9,12
D7S820: 9,10
THO1: 6,7
TPOX: 8
vWA: 14,17
Isoenzymes
ES-D, 1
G6PD, B
GLO-I, 1-2
PGM1, 1
Name of Depositor RB Owens
References

Arnstein P, et al. Propagation of human tumors in antithymocyte serum-treated mice. J. Natl. Cancer Inst. 52: 71-84, 1974. PubMed: 4544026

Ohsugi Y, et al. Tumorigenicity of human malignant lymphoblasts: comparative study with unmanipulated nude mice, antilymphocyte serum-treated nude mice, and X- irradiated nude mice. J. Natl. Cancer Inst. 65: 715-718, 1980. PubMed: 6932523

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
References

Arnstein P, et al. Propagation of human tumors in antithymocyte serum-treated mice. J. Natl. Cancer Inst. 52: 71-84, 1974. PubMed: 4544026

Ohsugi Y, et al. Tumorigenicity of human malignant lymphoblasts: comparative study with unmanipulated nude mice, antilymphocyte serum-treated nude mice, and X- irradiated nude mice. J. Natl. Cancer Inst. 65: 715-718, 1980. PubMed: 6932523